A practical reference on peptide backbone: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-03-25 and is reviewed periodically as new material appears.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Peptide backbone with a fatty diacid chain |
| Molecular weight | About 4813 Da | Calculated from the formula |
| Receptor targets | GIP and GLP-1 receptors | Dual agonist activity at both sites |
| Route of administration | Subcutaneous injection | No approved oral form at present |
| Elimination half-life | About 5 days | Supports extended intervals between administrations |
固体状态的 tirzepatide 通常以冻干粉形式保存，推荐在低温、避光、干燥条件下存放，常见区间为 2 至 8 摄氏度，长期保存可考虑更低温度并避免反复冻融。冻融循环会导致肽链聚集或析出，从而影响后续定量结果。容器密封性与湿度控制同样是稳定性研究中反复强调的因素。
溶解操作一般使用注射用水或适宜的水性缓冲液，必要时加入少量助溶剂以改善溶解速度，但应避免剧烈涡旋振荡，因为剪切力可能促进聚集。配制后的溶液在冷藏条件下的稳定时间通常短于固体形态，具体时限取决于浓度、缓冲体系与容器材质。是否加入防腐成分，则取决于用途是否为多次取样。
定量分析的主流方法是反相高效液相色谱联用紫外或质谱检测，利用肽在疏水固定相上的保留行为确定纯度与含量。对于生物基质中的浓度测定，常采用液相色谱串联质谱，并配合固相萃取或蛋白沉淀进行样品前处理。免疫分析法也可使用，但可能受到结构相关肽的交叉反应干扰。
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
Hummingbirds resemble sunbirds. The former live in the Americas and belong to an order or superorder including the swifts, while the latter live in Africa and Asia and are a family in the order Passeriformes. Also the nectar-feeding Hawaiian honeycreepers resemble the two and differs from other honeycreeper. Flightlessness has evolved in many different birds independently. However, taking this to a greater extreme, the terror birds, Gastornithiformes and dromornithids (ironically all extinct) all evolved the similar body shape (flightlessness, long legs, long necks, big heads), yet none of them were closely related. They also share the trait of being giant, flightless birds with vestigial wings, long legs, and long necks with the ratites, although they are not related. Certain longclaws (Macronyx) and meadowlarks (Sturnella) have essentially the same striking plumage pattern. The former inhabit Africa and the latter the Americas, and they belong to different lineages of Passerida. While they are ecologically quite similar, no satisfying explanation exists for the convergent plumage; it is best explained by sheer chance. Resemblances between swifts and swallows is due to convergent evolution. The chimney swift was originally identified as chimney swallow (Hirundo pelagica) by Carl Linnaeus in 1758, before being moved to the swift genus Chaetura by James Francis Stephens in 1825.
Elion (1918–1999), American biochemist and recipient of the 1988 Nobel Prize in Physiology or Medicine for innovative methods of rational drug design Conrad Elvehjem (1901–1962), American biochemist who identified two vitamins, nicotinic acid (niacin) and nicotinamide Harry Julius Emeléus (1903–1993), British inorganic chemist known for work on fluorine chemistry Gladys Anderson Emerson (1903–1984), American chemist and early nutritionist, and the first person to isolate Vitamin E Emil Erlenmeyer (1825–1909), German chemist known for the early development of the theory of chemical structure and formulating the Erlenmeyer rule. Richard R. Ernst (1933–2021), Swiss physical chemist, 1991 Nobel Prize in Chemistry for the development of Fourier transform nuclear magnetic resonance spectroscopy Gerhard Ertl (born 1936), German physical chemist who laid the foundation of modern surface chemistry, 2007 Nobel prize in chemistry Margaret C. Etter (1943–1992), American chemist and developer of solid state chemistry for crystalline organic compounds Hans von Euler-Chelpin (1873–1964), Swedish chemist, winner of the 1929 Nobel Prize in Chemistry for work on the fermentation of sugar and enzymes Henry Eyring (1901–1981), Mexico-born American theoretical chemist known for the absolute rate theory of chemical reactions
Transcriptional regulators, as well as a growing number of other factors, regulate the induction of beige fat. Four regulators of transcription are central to WAT browning and serve as targets for many of the molecules known to influence this process. These include peroxisome proliferator-activated receptor gamma (PPARγ), PRDM16, peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC-1α), and Early B-Cell Factor-2 (EBF2). The list of molecules that influence browning has grown in direct proportion to the popularity of this topic and is constantly evolving as more knowledge is acquired. Among these molecules are irisin and fibroblast growth factor 21 (FGF21), which have been well-studied and are believed to be important regulators of browning. Irisin is secreted from muscle in response to exercise and has been shown to increase browning by acting on beige preadipocytes. FGF21, a hormone secreted mainly by the liver, has garnered a great deal of interest after being identified as a potent stimulator of glucose uptake and a browning regulator through its effects on PGC-1α. It is increased in BAT during cold exposure and is thought to aid in resistance to diet-induced obesity FGF21 may also be secreted in response to exercise and a low protein diet, although the latter has not been thoroughly investigated. Data from these studies suggest that environmental factors like diet and exercise may be important mediators of browning.
=== Microscopic characteristics === In deposit, the spores are a deep reddish purple-brown color. The use of an optical microscope can reveal further details: the spores are oblong when seen in side view, and oblong to oval in frontal view, with dimensions of 10.5–15 by 6.5–8.5 μm. The basidia (spore bearing cells of the hymenium), are 20–31 by 5–9 μm, four-spored, and have clamps at their bases; there are no basidia found on the sterile gill edge. The cheilocystidia (cystidia on the gill edge) measure 15–30 by 4–7 μm, and are flask-shaped with long thin necks that are 1–3.5 μm wide. P. semilanceata does not have pleurocystidia (cystidia on the gill face). The cap cuticle is up to 90 μm thick, and is made of a tissue layer called an ixocutis—a gelatinized layer of hyphae lying parallel to the cap surface. The hyphae comprising the ixocutis are cylindrical, hyaline, and 1–3.5 μm wide. Immediately under the cap cuticle is the subpellis, made of hyphae that are 4–12 μm wide with yellowish-brown encrusted walls. There are clamp connections present in the hyphae of all tissues.
==== Asia ==== Under Xi, China initially took a more critical stance on North Korea due to its nuclear tests. However, starting in 2018, the relations started to improve due to meetings between Xi and North Korean leader Kim Jong Un. Xi has initially improved relationships with South Korea, and the two countries signed a free-trade agreement in December 2015. Starting in 2017, China's relationship with South Korea soured over the Terminal High Altitude Area Defence (THAAD), a missile defense system, deployment of the latter, but improved after South Korea halted further deployments on the THAAD. China–Japan relations have initially soured under Xi's administration; the most thorny issue between the two countries remains the dispute over the Senkaku Islands, which China calls Diaoyu. However, the relations later started to improve, though deteriorated in 2025 after comments made by Prime Minister Sanae Takaichi regarding a potential defense of Taiwan. Since Xi came to power, China has been rapidly building and militarizing islands in the South China Sea, a decision Study Times of the Central Party School said was personally taken by Xi. Relations between China and India had ups and downs under Xi. The two countries had a standoff in Depsang in 2013, and again had a standoff over a Chinese construction of a road in Doklam, a territory both claimed by Bhutan, India's ally, and China, in 2017. The most serious crisis in the relationship came when the two countries had a deadly clash in 2020 at the Line of Actual Control, leaving some soldiers dead.
Sources: en.wikipedia.org
Quest Diagnostics Incorporated is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains collaborative agreements with various hospitals and clinics across the globe. As of 2020, the company had approximately 48,000 employees, and it generated more than $7.7 billion in revenue in 2019. The company offers access to diagnostic testing services for cancer, cardiovascular disease, infectious disease, neurological disorders, COVID-19, and employment and court-ordered drug testing.
Schröder (1993, 2002) reviewed the issue of CPA dosage and recommended a dosage of 200 to 300 mg/day for CPA as a monotherapy and a dosage of 100 to 200 mg/day for CPA in combined androgen blockade (that is, CPA in combination with surgical or medical castration). However, the combination of CPA with castration for prostate cancer has been found to significantly decrease overall survival compared to castration alone. Hence, the use of CPA as the antiandrogen component in combined androgen blockade would appear not to be advisable. When used by intramuscular injection to treat prostate cancer, CPA is used at a dosage of 300 mg once a week. The combination of CPA with an estrogen such as ethinylestradiol sulfonate or low-dose diethylstilbestrol has been used as a form of combined androgen blockade and as an alternative to the combination of CPA with surgical or medical castration.
=== Cancer risk === Sirolimus may increase an individual's risk for contracting skin cancers from exposure to sunlight or UV radiation, and risk of developing lymphoma. In studies, the skin cancer risk under sirolimus was lower than under other immunosuppressants such as azathioprine and calcineurin inhibitors, and lower than under placebo.
=== Center of Excellence for Transgender Health (UCSF) === The Center of Excellence for Transgender Health at the University of California, San Francisco was established in 2009, dedicated to improving health equity for trans and gender nonconforming communities. The Center of Excellence for Transgender Health is a national advisory board composed of transgender leaders from across the United States, bringing expertise in the research of transgender health. Guidelines for Primary and Gender-Affirming Care of Transgender and Gender Nonbinary People contains guidelines developed by The Center of Excellence for Transgender Health that are widely used clinical guidelines for transgender healthcare.
=== Brazil === Between 2005 and 2021, Brazil had 1,576 suspected cases of CJD, of which 547 were confirmed. In August 2026, Brazilian aviation expert Lito Sousa was diagnosed with CJD. He died two months later, on October 1.
Sources: en.wikipedia.org
== Other uses == Chicago Engineering Design Team, a robotics team Eau de toilette Editor (abbrev: "edt." pl.: "edts.") Electronic Disturbance Theater, an activist and artist collective Evidential decision theory, a school of thought within decision theory Event-driven trading, institutional investors attempt to profit from a stock mispricing that may occur during or after a corporate event.
=== Silicone gel sheeting === Silicone gel sheeting is sometimes used to treat hypertrophic scars. Silicone gel sheets may improve the appearance of scars slightly compared with applying onion extract and may reduce pain compared with no treatment with silicone gel sheets or pressure garments. It is uncertain whether silicone gel sheets are more effective than other treatment methods.
== External links == Media related to Propranolol at Wikimedia Commons "Propranolol (Infantile Hemangioma): MedlinePlus Drug Information". MedlinePlus. "Propranolol ( Code - C62073 )". EVS Explore. "Propranolol Hydrochloride ( Code - C29382 )". EVS Explore.
Motixafortide, sold under the brand name Aphexda, is a medication used for the treatment of multiple myeloma. Motixafortide is a hematopoietic stem cell mobilizer and a CXCR4 antagonist. It is given by subcutaneous injection. The most common side effects include injection site reactions, pruritus, flushing, and back pain. Motixafortide was approved for medical use in the United States in September 2023.
Sources: en.wikipedia.org
It is a synthetic 39-amino-acid peptide that acts on two incretin receptors, the GIP receptor and the GLP-1 receptor. It is given by subcutaneous injection and has a circulating half-life of roughly five days. It is not a small molecule and is not absorbed usefully from the gut in conventional oral form.
Selective agents act on one receptor, while tirzepatide engages both GIP and GLP-1 receptors. The added GIP activity may contribute effects on insulin sensitivity and on fat metabolism. Whether the dual action produces meaningful clinical advantages beyond differences in potency is still being examined.
The downstream consequences of GIP receptor activation are not fully characterised in humans. It is also unclear how much each receptor contributes to appetite reduction and to shifts in body composition. Published work describes associations and proposed pathways rather than settled causal chains.
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.